PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

Key Inclusion Criteria: * Adult male or female subjects age 18-70 years * Negative serum beta-hCG pregnancy test for all women prior to starting treatment * Normal vital signs, body weight, BMI and laboratory test results * Willing to comply with dietary, fluid and lifestyle restrictions * Able to communicate well with the Investigator and comply with the requirements of the study. Additional Inclusion Criteria for hepatic impaired subjects * Physical signs consistent with hepatic impairment * CPC score consistent with degree of hepatic impairment * Serum creatinine \<=2xULN * ANC \>1000cells/mm3, hemaglobin \>9g/dL, platelet count \> 50,000/mm3 (group 2-3 only) Key Exclusion Criteria: * Significant neurologic or psychiatric disorder which could compromise participation in the study. * History of: seizures requiring anti-convulsant therapy; unstable COPD; GI or rectal bleeding 3 weeks prior to study start; Myocardial Infarction within 12 months; unstable or poorly controlled angina or other clinically significant heart disease; clinically significant urinary obstruction or difficulty voiding; clinically significant ECG abnormalities or long QT-interval syndrome; pancreatic injury or pancreatitis * Concurrent severe / uncontrolled medical conditions * Significant illness within 2 weeks prior to dosing or hospitalisation within 4 weeks prior to dosing * Any surgical or medical condition that may significantly affect absorption, distribution, metabolism or excretion of drugs * Clinically significant ECG abnormalities at screening * Cotinine levels greater than 500ng/mL (group 1-3) or smokers not willing to limit tobacco or nicotine products equivalent to 10 cigarettes per day (group 4 and 5) for 1 week prior to dosing and throughout hospital confinement * Consumption of alcohol within 3 days (group 1-3) or within 2 days (groups 4 and 5) prior to dosing or during the study. * Administration of CYP3A4/5 or P-gp inducing or inhibiting drugs within 14 days prior to dosing or during the study * Sexually active males unless they use condom during intercourse while taking midostaurin and for at least 3 months after the last exposure to drug. * Use of any prescription drug within 2 weeks or over the counter medication within 72 hours prior to dosing * Consumption of grapefruit, grapefruit juice, Seville oranges, start fruit / juice within 72 hours prior to dosing Additional exclusion criteria for healthy controls * Clinical evidence of liver disease or liver injury * Positive HBsAg or Hep C test result Additional exclusion criteria for hepatic impairment subjects * Symptoms or history of \>=G3 hepatic encephalopathy; surgical portosystemic shunt * PTT \>2.5xULN; INR \>3; Total bilirubin \>6mg/dL * Evidence of progressive liver disease within 4 weeks prior to starting study * Clinical evidence of severe \>=G3 ascites (groups 2 and 3)